United Research Institute
Welcome,         Profile    Billing    Logout  
 0 Trials 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Schultz, James
TRANSCEND-T2D-2, NCT06260722: Effect of Retatrutide Compared with Semaglutide in Adult Participants with Type 2 Diabetes and Inadequate Glycemic Control with Metformin with or Without SGLT2 Inhibitor

Recruiting
3
1250
Canada, US, RoW
Retatrutide, LY3437943, Semaglutide
Eli Lilly and Company
Diabetes Mellitus, Type 2
12/26
03/27
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
NCT06297603: Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

Recruiting
3
320
Europe, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Type 2 Diabetes
09/26
10/26
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Completed
3
928
Europe, Canada, Japan, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec
Eli Lilly and Company
Diabetes, Type 2 Diabetes
04/24
04/24
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
ACHIEVE-1, NCT05971940: A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

Active, not recruiting
3
520
Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Type 2 Diabetes
04/25
04/25
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting
3
1576
Japan, US, RoW
Orforglipron, LY3502970, Semaglutide
Eli Lilly and Company
Type 2 Diabetes
09/25
09/25
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT05860959: SUBLOCADE Long-term Outcomes

Recruiting
N/A
1200
Europe, Canada, US, RoW
Indivior Inc.
Opioid Use Disorder
08/27
08/27
Elsamra, Mohamed
NCT05860959: SUBLOCADE Long-term Outcomes

Recruiting
N/A
1200
Europe, Canada, US, RoW
Indivior Inc.
Opioid Use Disorder
08/27
08/27

Download Options